Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2637)

CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVES AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Change of Joint Company Secretary, Authorized Representatives and Process Agent

The board (the "**Board**") of directors (the "**Director(s)**") of Fujian Haixi Pharmaceuticals Co., Ltd. (the "**Company**") announces that Ms. Chan Hiu Lam ("**Ms. Chan**") has tendered her resignation as (i) a joint company secretary of the Company (the "**Joint Company Secretary(ies)**"); (ii) an authorized representative under Rule 3.05 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**")("**Authorized Representative under the Listing Rules**"); (iii) an authorized representative of the Company pursuant to Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong)(together with an Authorized Representative under the Listing Rules, the "**Authorized Representatives**") ; and (iv) the authorized person of the Company under Rule 19A.13(2) of the Listing Rules for the acceptance of service of process and notices on behalf of the Company in Hong Kong (the "**Process Agent**") with effect from 21 November 2025.

Ms. Chan confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board further announces that Ms. Lam Wai Yee Sophie ("**Ms. Lam**") has been appointed as a Joint Company Secretary, the Authorized Representatives and the Process Agent with effect from 21 November 2025. Ms. Lam will jointly perform the duties of company secretary with Ms. Zhang Junhuan ("**Ms. Zhang**"), who is currently the other Joint Company Secretary.

The biographical details of Ms. Lam are set out as follows:

Ms. Lam is currently a vice president of the corporate secretarial department at SWCS Corporate Services Group (Hong Kong) Limited, primarily responsible for company secretarial and compliance services for both listed and non-listed companies. With over 20 years of experience in the company secretarial and compliance profession, Ms. Lam has served as the company secretary and a joint company secretary of several companies listed on the Main Board of the Stock Exchange.

Ms. Lam holds a Bachelor of Arts (Honours) in Translation and a Postgraduate Diploma in Corporate Administration. She is a Chartered Secretary, a Chartered Governance Professional and a Fellow of The Chartered Governance Institute in the United Kingdom and The Hong Kong Chartered Governance Institute, and holds a Practitioner's Endorsement from The Hong Kong Chartered Governance Institute.

Waiver from Strict Compliance with Rules 3.28 and 8.17 of the Listing Rules

Due to the above-mentioned change of a Joint Company Secretary, the Company has applied for the Stock Exchange, and the Stock Exchange has granted a revised waiver (the "**Revised Waiver**") from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules in relation to the eligibility of Ms. Zhang to act as a Joint Company Secretary for a period from the effective date of appointment of Ms. Lam as a Joint Company Secretary (i.e. 21 November 2025) to 19 October 2028 (the "**Revised Waiver Period**") on the following conditions:

(i) Ms. Zhang must be assisted by Ms. Lam in discharging her functions as a Joint Company Secretary and in gaining the relevant experience as required under Rule 3.28 of the Listing Rules during the Revised Waiver Period; and

(ii) the Revised Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Revised Waiver Period, the Company must demonstrate and seek the Stock Exchange's confirmation that Ms. Zhang, having had the benefit of Ms. Lam's assistance during the Revised Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary. The Stock Exchange may withdraw or change the Revised Waiver if the Company's situation changes.

The Board would like to take this opportunity to express its gratitude to Ms. Chan for her contribution to the Company during her tenure of service, and to welcome Ms. Lam on her new appointments.

By Order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
Dr. Kang Xinshan
Chairman and Executive Director

Fujian, the PRC
21 November 2025

As at the date of this announcement, the executive Directors are Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi; the non-executive Directors are Mr. Xu Dong and Mr. Wang Xinkun; and the independent non-executive Directors are Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.